Cargando…
The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation
OBJECTIVE: To explore external validity of randomized controlled trials (RCTs) of hypertension within China from the view of sample representation. METHODS: Comprehensive literature searches were performed in Medline, Embase, Cochrane Central Register of Controlled Trials (CCTR) et al and advanced s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855762/ https://www.ncbi.nlm.nih.gov/pubmed/24324771 http://dx.doi.org/10.1371/journal.pone.0082324 |
_version_ | 1782294963991609344 |
---|---|
author | Zhang, Xin Wu, Yuxia Kang, Deying Wang, Jialiang Hong, Qi Le Peng, |
author_facet | Zhang, Xin Wu, Yuxia Kang, Deying Wang, Jialiang Hong, Qi Le Peng, |
author_sort | Zhang, Xin |
collection | PubMed |
description | OBJECTIVE: To explore external validity of randomized controlled trials (RCTs) of hypertension within China from the view of sample representation. METHODS: Comprehensive literature searches were performed in Medline, Embase, Cochrane Central Register of Controlled Trials (CCTR) et al and advanced search strategies were used to locate hypertension RCTs as well as observational studies conducted in China during 1996 to 2009 synchronously. The risk of bias in RCTs and observational studies was assessed by two modified scales respectively, and then both types of studies with 3 or more grading scores were included for the purpose of evaluating of external validity. Following that the study characteristics relative to sample representation were extracted from RCTs and observational studies synchronously, and the later were taken as external references for validating sample representation of RCTs. RESULTS: 226 hypertension RCTs and 21 observational studies were included for final analysis. Comparing samples with observational studies, the mean age of samples within RCTs was 54.46 years, significantly lower than that of observational studies (66.35 years) (P=0.002). The average disease course in patients of RCTs was 3.89 years and grade III hypertensive patients accounted for 17%; both were lower than that of the observational studies (12.96 years, P<0.001; 34%, P=0.026 respectively). In addition, the proportions of patients with complications due to heart failure, stroke, diabetes, or coronary heart disease in RCTs were 8%, 5%, 12% and 11% correspondingly, all of which were significantly less than that of observational studies (11%, 18%, 17% and 29%). CONCLUSION: Sample characteristics within hypertension RCTs were significantly different from those in observational studies. The samples in most RCTs were under-represented. It’s feasible to take samples of observational studies as a mirror of the actual composition of hypertension patients in the real world, if the reporting of observational studies is abundant and available. |
format | Online Article Text |
id | pubmed-3855762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38557622013-12-09 The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation Zhang, Xin Wu, Yuxia Kang, Deying Wang, Jialiang Hong, Qi Le Peng, PLoS One Research Article OBJECTIVE: To explore external validity of randomized controlled trials (RCTs) of hypertension within China from the view of sample representation. METHODS: Comprehensive literature searches were performed in Medline, Embase, Cochrane Central Register of Controlled Trials (CCTR) et al and advanced search strategies were used to locate hypertension RCTs as well as observational studies conducted in China during 1996 to 2009 synchronously. The risk of bias in RCTs and observational studies was assessed by two modified scales respectively, and then both types of studies with 3 or more grading scores were included for the purpose of evaluating of external validity. Following that the study characteristics relative to sample representation were extracted from RCTs and observational studies synchronously, and the later were taken as external references for validating sample representation of RCTs. RESULTS: 226 hypertension RCTs and 21 observational studies were included for final analysis. Comparing samples with observational studies, the mean age of samples within RCTs was 54.46 years, significantly lower than that of observational studies (66.35 years) (P=0.002). The average disease course in patients of RCTs was 3.89 years and grade III hypertensive patients accounted for 17%; both were lower than that of the observational studies (12.96 years, P<0.001; 34%, P=0.026 respectively). In addition, the proportions of patients with complications due to heart failure, stroke, diabetes, or coronary heart disease in RCTs were 8%, 5%, 12% and 11% correspondingly, all of which were significantly less than that of observational studies (11%, 18%, 17% and 29%). CONCLUSION: Sample characteristics within hypertension RCTs were significantly different from those in observational studies. The samples in most RCTs were under-represented. It’s feasible to take samples of observational studies as a mirror of the actual composition of hypertension patients in the real world, if the reporting of observational studies is abundant and available. Public Library of Science 2013-12-06 /pmc/articles/PMC3855762/ /pubmed/24324771 http://dx.doi.org/10.1371/journal.pone.0082324 Text en © 2013 Zhang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zhang, Xin Wu, Yuxia Kang, Deying Wang, Jialiang Hong, Qi Le Peng, The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation |
title | The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation |
title_full | The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation |
title_fullStr | The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation |
title_full_unstemmed | The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation |
title_short | The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation |
title_sort | external validity of randomized controlled trials of hypertension within china: from the perspective of sample representation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855762/ https://www.ncbi.nlm.nih.gov/pubmed/24324771 http://dx.doi.org/10.1371/journal.pone.0082324 |
work_keys_str_mv | AT zhangxin theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT wuyuxia theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT kangdeying theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT wangjialiang theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT hongqi theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT lepeng theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT zhangxin externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT wuyuxia externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT kangdeying externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT wangjialiang externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT hongqi externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation AT lepeng externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation |